Pathological angiogenesis inhibitor and application thereof

An angiogenesis and pathological technology, applied in the field of medicine, can solve problems such as the absence of diseases related to abnormal blood vessels, and achieve the best therapeutic effect and prolong the survival time.

Active Publication Date: 2021-12-28
陈晓文
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, many inhibitors related to energy metabolism pathways have been used in clinical research to treat related cancers, but not for other diseases with abnormal blood vessel related factors Related clinical research reports (Iannelli et al.2018)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pathological angiogenesis inhibitor and application thereof
  • Pathological angiogenesis inhibitor and application thereof
  • Pathological angiogenesis inhibitor and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0086] Example 1 shRNA-mediated knockdown of IDI1

[0087] Two primer sequences ShIDI1-1 and ShIDI1-2 targeting different sites of human IDI1 gene (NCBI gene accession number 3422) were synthesized and cloned into the retroviral shRNApLKO.1 vector (Addgene). in,

[0088] ShIDI1-1 sequence SEQ ID NO: 1:

[0089] 5'-CCGGCGTGTTGTAGTCATCCATTAACTCGAGTTAATGGATGACTACAACACGTTTTTG-3';

[0090] ShIDI1-2 sequence SEQ ID NO: 2:

[0091] 5'-CCGGCCAGATCCCAATGAGATTAAACTCGAGTTTAATCTCATTGGGATCTGGTTTTTG-3'.

[0092] In HEK293 cells ( CRL-1573 TM ) using the PEI method to synthesize retroviruses. Human umbilical vein endothelial cells (HUVEC) were transfected with the virus produced ( CRL-1730 TM ). After 48 hours or 72 hours after transfection, the cell protein was harvested and the knockdown efficiency of the IDI1 gene was detected by Western blot. The results were as follows figure 2 As shown in A. Depend on figure 2 A It can be determined that the IDI1 gene is knocked down ef...

Embodiment 2

[0095] Example 2 Effect of IDI1 overexpression on primary human endothelial cells

[0096]In order to study whether the overexpression of IDI1 will affect the function of endothelial cells, the inventors cloned and constructed the retroviral vector of IDI1 overexpression and expressed it in HEK293 cells ( CRL-1573 TM ) to synthesize the retrovirus. HUVEC cells were transfected with the virus produced. After 48 hours or 72 hours after transfection, the expression level of IDI1 was significantly increased, and the results were as follows: image 3 As shown in A. image 3 A shows the expression levels of IDI1 in the control (control) and IDI1 overexpression group cells (OE, overexpression) detected by Western blot. image 3 B shows the migration ability of control and IDI1 overexpressed endothelial cells using the wound healing method, which shows the healing situation of control and IDI1 overexpressed endothelial cells (OE) at 0 hours, 6 hours and 10 hours after wound forma...

Embodiment 3

[0097] Example 3 idi1 zebrafish mutant model

[0098] In order to study the function of idi1 gene in vivo, a zebrafish idi1 gene mutant line was identified and phenotyped. The allele (allele) La014590Tg of this mutation was obtained from the Zebrafish Information and Research Center (ZIRC). A pair of primers SEQ ID NO:3 and 4 are used to determine the allele of mutation, wherein the structure of wild type and mutant idi1 allele is as follows Figure 4 As shown in A.

[0099] Forward primer sequence SEQ ID NO:3:

[0100] 5'-AAAGACCCCCACCTGTAGGTTTG-3';

[0101] Reverse primer sequence SEQ ID NO:4:

[0102] 5'-ACCGTTACCAGAGAGCTAGT-3'.

[0103] Selfing of Idi1 heterozygotes was used to generate mutant zebrafish embryos. The zebrafish (2dpf, days post-hybridization) control and mutant embryos developed to 2 days were collected, and the expression level of IDI1 protein was detected by Western Blot using an anti-idi1 antibody (GeneTex, catalog number GTX106100), and it was foun...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a pathological angiogenesis inhibitor and application thereof, namely application of an isopentenyl pyrophosphate isomerase 1 inhibitor in preparation of the pathological angiogenesis inhibitor and application of the isopentenyl pyrophosphate isomerase 1 inhibitor in preparation of drugs for preventing and / or treating diseases related to pathological angiogenesis. The pathological angiogenesis inhibitor can more effectively inhibit pathological angiogenesis compared with the conventional means for inhibiting angiogenesis signal pathways, so that pathological angiogenesis related diseases can be more effectively prevented and / or treated.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to a pathological angiogenesis inhibitor and a medicine for preventing and / or treating diseases related to pathological angiogenesis. Specifically, the present invention relates to the use of the isopentenyl diphosphate isomerase 1 inhibitor in the preparation of inhibitors of pathological angiogenesis and in the preparation of medicines for preventing and / or treating diseases related to pathological angiogenesis. Background technique [0002] Angiogenesis refers to the process of growing new blood vessels from existing blood vessels, which is an important biological process to maintain normal life body development, physiological activities, and pathological formation (Carmeliet 2004). Angiogenesis is regulated by many complex signaling pathways. Abnormalities in these signaling pathways can cause abnormal angiogenesis and lead to serious pathological consequences, such as cancer and other di...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/7088A61K31/665A61K31/661A61P9/10A61P27/02A61P35/00A61P35/02A61P37/02A61P13/12A61P19/02A61P29/00
CPCA61K45/00A61K31/7088A61K31/665A61K31/661A61P9/10A61P27/02A61P35/00A61P35/02A61P37/02A61P13/12A61P19/02A61P29/00
Inventor 陈晓文
Owner 陈晓文
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products